{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:34:42Z","timestamp":1794015282811,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Rationale.<\/jats:title>\n                <jats:p>Classic psychedelics are currently being studied as novel treatments for a range of psychiatric disorders. However, research on how psychedelics interact with other psychoactive substances remains scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The current study aimed to explore the subjective effects of psychedelics when used alongside cannabis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants (<jats:italic>n<\/jats:italic>\u2009=\u2009321) completed a set of online surveys at 2 time points: 7\u00a0days before, and 1\u00a0day after a planned experience with a serotonergic psychedelic. The collected data included demographics, environmental factors (so-called setting) and five validated questionnaires: Mystical Experience Questionnaire (MEQ), visual subscales of Altered States of Consciousness Questionnaire (ASC-Vis), Challenging Experience Questionnaire (CEQ), Ego Dissolution Inventory (EDI) and Emotional Breakthrough Inventory (EBI). Participants were grouped according to whether they had reported using no cannabis (<jats:italic>n<\/jats:italic>\u2009=\u2009195) or low (<jats:italic>n<\/jats:italic>\u2009=\u200953), medium (<jats:italic>n<\/jats:italic>\u2009=\u200945) or high (<jats:italic>n<\/jats:italic>\u2009=\u200928) dose, directly concomitant with the psychedelic. Multivariate analysis of covariance (MANCOVA) and contrasts was used to analyse differences in subjective effects between groups while controlling for potential confounding contextual \u2018setting\u2019 variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The simultaneous use of cannabis together with classic serotonergic psychedelics was associated with more intense psychedelic experience across a range of measures: a linear relationship was found between dose and MEQ, ASC-Vis and EDI scores, while a quadratic relationship was found for CEQ scores. No relationship was found between the dose of cannabis and the EBI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Results imply a possible interaction between the cannabis and psychedelic on acute subjective experiences; however, design limitations hamper our ability to draw firm inferences on directions of causality and the clinical implications of any such interactions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00213-021-05999-1","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T01:02:28Z","timestamp":1635987748000},"page":"1425-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4159-7176","authenticated-orcid":false,"given":"Joanna","family":"Kuc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Kettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erritzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Haijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Kaelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"5999_CR1","doi-asserted-by":"publisher","DOI":"10.3109\/10826087609058801","author":"C Adamec","year":"1976","unstructured":"Adamec C, Pihl RO, Leiter L (1976) An analysis of the subjective marijuana experience. Subst Use Misuse. https:\/\/doi.org\/10.3109\/10826087609058801","journal-title":"Subst Use Misuse"},{"key":"5999_CR2","doi-asserted-by":"publisher","DOI":"10.2174\/138161212802884852","author":"Z Atakan","year":"2012","unstructured":"Atakan Z, Morrison P, G. Bossong M, et al (2012) The effect of cannabis on perception of time: a critical review. Curr Pharm Des. https:\/\/doi.org\/10.2174\/138161212802884852","journal-title":"Curr Pharm Des"},{"key":"5999_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/pch\/13.1.53","volume":"13","author":"F Baltzer","year":"2008","unstructured":"Baltzer F, Elliott A, Katzman D et al (2008) Harm reduction: an approach to reducing risky health behaviours in adolescents. Paediatr Child Health (oxford) 13:53\u201356. https:\/\/doi.org\/10.1093\/pch\/13.1.53","journal-title":"Paediatr Child Health (oxford)"},{"key":"5999_CR4","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","volume":"27","author":"FR Bambico","year":"2007","unstructured":"Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27:11700\u201311711. https:\/\/doi.org\/10.1523\/JNEUROSCI.1636-07.2007","journal-title":"J Neurosci"},{"key":"5999_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116678781","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos JMS et al (2016) The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881116678781","journal-title":"J Psychopharmacol"},{"key":"5999_CR6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182\u20131190. https:\/\/doi.org\/10.1177\/0269881115609019","journal-title":"J Psychopharmacol"},{"key":"5999_CR7","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0052","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Schlienz NJ, Lembeck N et al (2018) \u201cHallucinations\u201d following acute cannabis dosing: a case report and comparison to other hallucinogenic drugs. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/can.2017.0052","journal-title":"Cannabis Cannabinoid Res"},{"key":"5999_CR8","doi-asserted-by":"publisher","DOI":"10.3768\/rtipress.2016.op.0035.1611","author":"DG Barrus","year":"2016","unstructured":"Barrus DG, Capogrossi KL, Cates SC et al (2016) Tasty THC: promises and challenges of cannabis edibles. Methods Rep RTI Press. https:\/\/doi.org\/10.3768\/rtipress.2016.op.0035.1611","journal-title":"Methods Rep RTI Press"},{"key":"5999_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7334\/psicothema2016.383","volume":"29","author":"MJ Blanca","year":"2017","unstructured":"Blanca MJ, Alarc\u00f3n R, Arnau J et al (2017) Datos no normales: \u00bfes el ANOVA una opci\u00f3n v\u00e1lida? Psicothema 29:552\u2013557. https:\/\/doi.org\/10.7334\/psicothema2016.383","journal-title":"Psicothema"},{"key":"5999_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA et al (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881114565144","journal-title":"J Psychopharmacol"},{"key":"5999_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/her\/16.4.457","author":"A Boys","year":"2001","unstructured":"Boys A (2001) Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res. https:\/\/doi.org\/10.1093\/her\/16.4.457","journal-title":"Health Educ Res"},{"key":"5999_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jnc.12716","volume":"130","author":"A Burokas","year":"2014","unstructured":"Burokas A, Mart\u00edn-Garc\u00eda E, Guti\u00e9rrez-Cuesta J et al (2014) Relationships between serotonergic and cannabinoid system in depressive-like behavior: A PET study with [11C]-DASB. J Neurochem 130:126\u2013135. https:\/\/doi.org\/10.1111\/jnc.12716","journal-title":"J Neurochem"},{"key":"5999_CR13","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2017.0684","author":"I Byock","year":"2018","unstructured":"Byock I (2018) Taking Psychedelics Seriously. J Palliat Med. https:\/\/doi.org\/10.1089\/jpm.2017.0684","journal-title":"J Palliat Med"},{"key":"5999_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ et al (2018a) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235:399\u2013408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x","journal-title":"Psychopharmacology"},{"key":"5999_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 3:619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","journal-title":"The Lancet Psychiatry"},{"key":"5999_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/0269881113494107","volume":"27","author":"RL Carhart-Harris","year":"2013","unstructured":"Carhart-Harris RL, Brugger S, Nutt DJ, Stone JM (2013) Psychiatry\u2019s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. J Psychopharmacol 27:771\u2013778. https:\/\/doi.org\/10.1177\/0269881113494107","journal-title":"J Psychopharmacol"},{"key":"5999_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol 31:1091\u20131120","journal-title":"J Psychopharmacol"},{"key":"5999_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Roseman L, Haijen E et al (2018b) Psychedelics and the essential importance of context. J Psychopharmacol 32:725\u2013731. https:\/\/doi.org\/10.1177\/0269881118754710","journal-title":"J Psychopharmacol"},{"key":"5999_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/adb.12116","volume":"20","author":"J Ceccarini","year":"2015","unstructured":"Ceccarini J, Kuepper R, Kemels D et al (2015) [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol 20:357\u2013367. https:\/\/doi.org\/10.1111\/adb.12116","journal-title":"Addict Biol"},{"key":"5999_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00135","author":"M Chary","year":"2018","unstructured":"Chary M, Yi D, Manini AF (2018) Candyflipping and other combinations: identifying drug-drug combinations from an online forum. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2018.00135","journal-title":"Front Psychiatry"},{"key":"5999_CR21","doi-asserted-by":"publisher","DOI":"10.2174\/1874473708666150107121331","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. https:\/\/doi.org\/10.2174\/1874473708666150107121331","journal-title":"Curr Drug Abuse Rev"},{"key":"5999_CR22","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000084","author":"A Garcia-Romeu","year":"2016","unstructured":"Garcia-Romeu A, Kersgaard B, Addy PH (2016) Clinical applications of hallucinogens: a review. Exp Clin Psychopharmacol. https:\/\/doi.org\/10.1037\/pha0000084","journal-title":"Exp Clin Psychopharmacol"},{"key":"5999_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","volume":"76","author":"G Gobbi","year":"2019","unstructured":"Gobbi G, Atkin T, Zytynski T et al (2019) Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiat 76:426\u2013434. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4500","journal-title":"JAMA Psychiat"},{"key":"5999_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"5999_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2358-5","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA et al (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-011-2358-5","journal-title":"Psychopharmacology"},{"key":"5999_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187:268\u2013283. https:\/\/doi.org\/10.1007\/s00213-006-0457-5","journal-title":"Psychopharmacology"},{"key":"5999_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/10826080802484702","author":"C Grov","year":"2009","unstructured":"Grov C, Kelly BC, Parsons JT (2009) Polydrug use among club-going young adults recruited through time-space sampling. Subst Use Misuse. https:\/\/doi.org\/10.1080\/10826080802484702","journal-title":"Subst Use Misuse"},{"key":"5999_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00897","author":"ECHM Haijen","year":"2018","unstructured":"Haijen ECHM, Kaelen M, Roseman L et al (2018) Predicting responses to psychedelics: a prospective study. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.00897","journal-title":"Front Pharmacol"},{"key":"5999_CR29","doi-asserted-by":"crossref","unstructured":"Haj-Dahmane S, Shen RY (2011) Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology","DOI":"10.1016\/j.neuropharm.2011.02.016"},{"key":"5999_CR30","doi-asserted-by":"crossref","unstructured":"Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology","DOI":"10.1016\/j.neuropharm.2011.01.017"},{"key":"5999_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.copsyc.2020.07.027","volume":"38","author":"I Hamilton","year":"2021","unstructured":"Hamilton I, Sumnall H (2021) Are we any closer to identifying a causal relationship between cannabis and psychosis? Curr Opin Psychol 38:56\u201360","journal-title":"Curr Opin Psychol"},{"key":"5999_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/02791072.2017.1290855","volume":"49","author":"A Heink","year":"2017","unstructured":"Heink A, Katsikas S, Lange-Altman T (2017) Examination of the phenomenology of the ibogaine treatment experience: role of altered states of consciousness and psychedelic experiences. J Psychoactive Drugs 49:201\u2013208. https:\/\/doi.org\/10.1080\/02791072.2017.1290855","journal-title":"J Psychoactive Drugs"},{"key":"5999_CR33","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/s41386-018-0076-y","volume":"43","author":"I Ibarra-Lecue","year":"2018","unstructured":"Ibarra-Lecue I, Mollinedo-Gajate I, Meana JJ et al (2018) Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt\/mTOR pathway. Neuropsychopharmacology 43:2028\u20132035. https:\/\/doi.org\/10.1038\/s41386-018-0076-y","journal-title":"Neuropsychopharmacology"},{"key":"5999_CR34","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0034","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/can.2016.0034","journal-title":"Cannabis Cannabinoid Res"},{"key":"5999_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/BF00403684","volume":"14","author":"H Isbell","year":"1969","unstructured":"Isbell H, Jasinski DR (1969) A comparison of LSD-25 with (-)-\u03949-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. Psychopharmacologia 14:115\u2013123. https:\/\/doi.org\/10.1007\/BF00403684","journal-title":"Psychopharmacologia"},{"key":"5999_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881114548296","journal-title":"J Psychopharmacol"},{"key":"5999_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00730","author":"BS Kamal","year":"2018","unstructured":"Kamal BS, Kamal F, Lantela DE (2018) Cannabis and the anxiety of fragmentation\u2014a systems approach for finding an anxiolytic cannabis chemotype. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2018.00730","journal-title":"Front Neurosci"},{"key":"5999_CR38","doi-asserted-by":"publisher","unstructured":"Kettner H, Rosas FE, Timmermann C, et al (2021) Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Front Pharmacol 12https:\/\/doi.org\/10.3389\/fphar.2021.623985","DOI":"10.3389\/fphar.2021.623985"},{"key":"5999_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4097\/KJA.D.18.00242","volume":"71","author":"S Lee","year":"2018","unstructured":"Lee S, Lee DK (2018) What is the proper way to apply the multiple comparison test? Korean J Anesthesiol 71:353. https:\/\/doi.org\/10.4097\/KJA.D.18.00242","journal-title":"Korean J Anesthesiol"},{"key":"5999_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2234","author":"CL Licht","year":"2012","unstructured":"Licht CL, Christoffersen M, Okholm M et al (2012) Simultaneous polysubstance use among Danish 3,4- methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. Hum Psychopharmacol. https:\/\/doi.org\/10.1002\/hup.2234","journal-title":"Hum Psychopharmacol"},{"key":"5999_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4453-0","author":"ME Liechti","year":"2017","unstructured":"Liechti ME, Dolder PC, Schmid Y (2017) Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-016-4453-0","journal-title":"Psychopharmacology"},{"key":"5999_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","volume":"103","author":"R Linge","year":"2016","unstructured":"Linge R, Jim\u00e9nez-S\u00e1nchez L, Campa L et al (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology 103:16\u201326. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.12.017","journal-title":"Neuropharmacology"},{"key":"5999_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-5906.2012.01685.x","author":"KA MacLean","year":"2012","unstructured":"MacLean KA, Leoutsakos JMS, Johnson MW, Griffiths RR (2012) Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig. https:\/\/doi.org\/10.1111\/j.1468-5906.2012.01685.x","journal-title":"J Sci Study Relig"},{"key":"5999_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3959(98)00045-0","author":"E MacRae","year":"1998","unstructured":"MacRae E (1998) Santo Daime and Santa Maria - The licit ritual use of ayabuasca and the illicit use of cannabis in a Brazilian Amazonian religion. Int J Drug Policy. https:\/\/doi.org\/10.1016\/S0955-3959(98)00045-0","journal-title":"Int J Drug Policy"},{"key":"5999_CR45","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fnbeh.2020.611278","volume":"14","author":"C Mart\u00ednez-Aguirre","year":"2020","unstructured":"Mart\u00ednez-Aguirre C, Carmona-Cruz F, Velasco AL et al (2020) Cannabidiol acts at 5-HT1A receptors in the human brain: relevance for treating temporal lobe epilepsy. Front Behav Neurosci 14:233. https:\/\/doi.org\/10.3389\/fnbeh.2020.611278","journal-title":"Front Behav Neurosci"},{"key":"5999_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/00221325.1959.10532434","volume":"94","author":"AH Maslow","year":"1959","unstructured":"Maslow AH (1959) Cognition of being in the peak experiences. J Genet Psychol 94:43\u201366. https:\/\/doi.org\/10.1080\/00221325.1959.10532434","journal-title":"J Genet Psychol"},{"key":"5999_CR47","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.v67n1110","journal-title":"J Clin Psychiatry"},{"key":"5999_CR48","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"5999_CR49","doi-asserted-by":"crossref","unstructured":"Nichols DE (2000) Role of serotoninergic neurons and 5-HT receptors in the action of hallucinogens. In: Serotonergic Neurons and 5-HT Receptors in the CNS. 563\u2013585","DOI":"10.1007\/978-3-642-60921-3_21"},{"key":"5999_CR50","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/02791072.2017.1312643","volume":"49","author":"MM Nour","year":"2017","unstructured":"Nour MM, Evans L, Carhart-Harris RL (2017) Psychedelics, personality and political perspectives. J Psychoactive Drugs 49:182\u2013191. https:\/\/doi.org\/10.1080\/02791072.2017.1312643","journal-title":"J Psychoactive Drugs"},{"key":"5999_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00269","author":"MM Nour","year":"2016","unstructured":"Nour MM, Evans L, Nutt D, Carhart-Harris RL (2016) Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). Front Hum Neurosci. https:\/\/doi.org\/10.3389\/fnhum.2016.00269","journal-title":"Front Hum Neurosci"},{"key":"5999_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1974.10480224","author":"CL Olson","year":"1974","unstructured":"Olson CL (1974) Comparative robustness of six tests in multivariate analysis of variance. J Am Stat Assoc. https:\/\/doi.org\/10.1080\/01621459.1974.10480224","journal-title":"J Am Stat Assoc"},{"key":"5999_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.212.11.1856","author":"WN Pahnke","year":"1971","unstructured":"Pahnke WN, Kurland AA, Unger S et al (1971) The experimental use of psychedelic (LSD) psychotherapy. Int Z Klin Pharmakol Ther Toxikol. https:\/\/doi.org\/10.1001\/jama.212.11.1856","journal-title":"Int Z Klin Pharmakol Ther Toxikol"},{"key":"5999_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1970.10471366","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Richards WA (1970) Implications of LSD and experimental mysticism. J Psychoactive Drugs. https:\/\/doi.org\/10.1080\/02791072.1970.10471366","journal-title":"J Psychoactive Drugs"},{"key":"5999_CR55","doi-asserted-by":"publisher","DOI":"10.3109\/10826087909054574","author":"RO Pihl","year":"1979","unstructured":"Pihl RO, Shea D, Costa L (1979) Dimensions of the subjective marijuana experience. Subst Use Misuse. https:\/\/doi.org\/10.3109\/10826087909054574","journal-title":"Subst Use Misuse"},{"key":"5999_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","volume":"156","author":"LBM Resstel","year":"2009","unstructured":"Resstel LBM, Tavares RF, Lisboa SFS et al (2009) 5-HT 1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156:181\u2013188. https:\/\/doi.org\/10.1111\/j.1476-5381.2008.00046.x","journal-title":"Br J Pharmacol"},{"key":"5999_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974","author":"L Roseman","year":"2019","unstructured":"Roseman L, Haijen E, Idialu-Ikato K et al (2019) Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881119855974","journal-title":"J Psychopharmacol"},{"key":"5999_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2017.00974","journal-title":"Front Pharmacol"},{"key":"5999_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"key":"5999_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01473-8","author":"MD Schechter","year":"1998","unstructured":"Schechter MD (1998) \u201cCandyflipping\u201d: Synergistic discriminative effect of LSD and MDMA. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/S0014-2999(97)01473-8","journal-title":"Eur J Pharmacol"},{"key":"5999_CR61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/0269881120959604","volume":"35","author":"Y Schmid","year":"2021","unstructured":"Schmid Y, Gasser P, Oehen P, Liechti ME (2021) Acute subjective effects in LSD- and MDMA-assisted psychotherapy. J Psychopharmacol 35:362\u2013374. https:\/\/doi.org\/10.1177\/0269881120959604","journal-title":"J Psychopharmacol"},{"key":"5999_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1027\/1614-2241\/a000016","volume":"6","author":"E Schmider","year":"2010","unstructured":"Schmider E, Ziegler M, Danay E et al (2010) Is it really robust?: reinvestigating the robustness of ANOVA against violations of the normal distribution assumption. Methodology 6:147\u2013151. https:\/\/doi.org\/10.1027\/1614-2241\/a000016","journal-title":"Methodology"},{"key":"5999_CR63","volume-title":"Mysticism and Philosophy","author":"W Stace","year":"1960","unstructured":"Stace W (1960) Mysticism and Philosophy. Palgrave Macmillan, Sumas, USA"},{"key":"5999_CR64","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1021\/acsptsci.0c00169","volume":"4","author":"CS Stauffer","year":"2021","unstructured":"Stauffer CS, Anderson BT, Ortigo KM, Woolley J (2021) Psilocybin-assisted group therapy and attachment: observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience. ACS Pharmacol Transl Sci 4:526\u2013532. https:\/\/doi.org\/10.1021\/acsptsci.0c00169","journal-title":"ACS Pharmacol Transl Sci"},{"key":"5999_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881120959609","volume":"35","author":"DS Stenb\u00e6k","year":"2021","unstructured":"Stenb\u00e6k DS, Madsen MK, Ozenne B et al (2021) Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. J Psychopharmacol 35:459\u2013468. https:\/\/doi.org\/10.1177\/0269881120959609","journal-title":"J Psychopharmacol"},{"key":"5999_CR66","doi-asserted-by":"publisher","unstructured":"Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7https:\/\/doi.org\/10.1371\/journal.pone.0030800","DOI":"10.1371\/journal.pone.0030800"},{"key":"5999_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0012412","journal-title":"PLoS ONE"},{"key":"5999_CR68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/jgme-d-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan GM, Feinn R (2012) Using effect size\u2014or why the P value is not enough. J Grad Med Educ 4:279\u2013282. https:\/\/doi.org\/10.4300\/jgme-d-12-00156.1","journal-title":"J Grad Med Educ"},{"key":"5999_CR69","doi-asserted-by":"crossref","unstructured":"Swanson LR (2018) Unifying theories of psychedelic drug effects. Front. Pharmacol","DOI":"10.3389\/fphar.2018.00172"},{"key":"5999_CR70","first-page":"120","volume":"17","author":"A Szab\u00f3","year":"2015","unstructured":"Szab\u00f3 A, Kazai A, Frecska E, Brys Z (2015) Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca. Neuropsychopharmacol Hung 17:120\u2013128","journal-title":"Neuropsychopharmacol Hung"},{"key":"5999_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/226701a0","author":"CT Tart","year":"1970","unstructured":"Tart CT (1970) Marijuana intoxication: Common experiences. Nature. https:\/\/doi.org\/10.1038\/226701a0","journal-title":"Nature"},{"key":"5999_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/da.22664","volume-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","author":"J Turna","year":"2017","unstructured":"Turna J, Patterson B, Van Ameringen M (2017) Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress, Anxiety"},{"key":"5999_CR73","doi-asserted-by":"publisher","first-page":"e1002194","DOI":"10.1371\/journal.pbio.1002194","volume":"13","author":"X Vi\u00f1als","year":"2015","unstructured":"Vi\u00f1als X, Moreno E, Lanfumey L et al (2015) Cognitive impairment induced by Delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLOS Biol 13:e1002194. https:\/\/doi.org\/10.1371\/journal.pbio.1002194","journal-title":"PLOS Biol"},{"key":"5999_CR74","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J et al (2017) Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol 57:520\u2013564. https:\/\/doi.org\/10.1177\/0022167817709585","journal-title":"J Humanist Psychol"},{"key":"5999_CR75","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.15r01786","author":"S Yarnell","year":"2015","unstructured":"Yarnell S (2015) The use of medicinal marijuana for posttraumatic stress disorder. Prim Care Companion CNS Disord. https:\/\/doi.org\/10.4088\/pcc.15r01786","journal-title":"Prim Care Companion CNS Disord"},{"key":"5999_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119849814","author":"Y Zaytseva","year":"2019","unstructured":"Zaytseva Y, Hor\u00e1\u010dek J, Hlinka J et al (2019) Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881119849814","journal-title":"J Psychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05999-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T05:09:27Z","timestamp":1652677767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05999-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5999"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05999-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"6 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joanna Kuc is currently an employee at COMPASS Pathways plc. This work is unrelated to COMPASS Pathways plc. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}